Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
Cytopathology. 2024 Nov;35(6):706-714. doi: 10.1111/cyt.13432. Epub 2024 Aug 7.
The Modified Masood Scoring Index (MMSI) categorizes breast fine needle aspirates into four categories non-proliferative breast diseases (PBD), PBD without atypia, PBD with atypia and carcinoma in situ/carcinoma. The International Academy of Cytology Yokohama System classifies the aspirates into five categories - inadequate, benign, atypical, suspicious, and malignant. Very few studies have been conducted so far to compare the diagnostic accuracy of this system.
The objectives of the study were to classify breast fine needle aspirates according to the MMSI and IAC Yokohama and assess their risk of malignancy (ROM) and performance parameters.
All breast FNAs received from June 2020 to May 2023 were classified according to the MMSI and IAC Yokohama. Using histopathological diagnosis as the gold standard, ROM and performance parameters were calculated.
Out of the 559 breast fine needle aspirates, the histopathological correlation was available for 337 cases. The ROM for non-PBD, PBD without atypia, PBD with atypia and carcinoma in situ/carcinoma categories were 0%, 1.2%, 9.1% and 93%, respectively. The ROM for each of the categories of Yokohama system was 16.6%, 1.1%, 4.3%, 86.2% and 97.6%, respectively. The values for the sensitivity, specificity, PPV, NPV and diagnostic accuracy were slightly higher for IAC Yokohama (97.3%, 97.2%, 94.7%, 98.6% and 97.2%, respectively) than the MMSI (96.4%, 96.2%, 93%, 98.1% and 96.3%, respectively). Furthermore, another shortfall of MMSI is the inability to compare the Inadequate category of the Yokohama system.
Overall Yokohama system proved to be a better system for categorizing breast lesions on FNAB as the scoring system provides more objective categorization and minimizes false positive and false negative cases.
改良的 Masood 评分指数(MMSI)将乳腺细针抽吸物分为四类:非增殖性乳腺疾病(PBD)、无非典型增生的 PBD、有非典型增生的 PBD 和原位癌/癌。国际细胞学协会横滨系统将抽吸物分为五类——不充分、良性、非典型、可疑和恶性。迄今为止,很少有研究比较该系统的诊断准确性。
本研究的目的是根据 MMSI 和 IAC 横滨系统对乳腺细针抽吸物进行分类,并评估其恶性风险(ROM)和性能参数。
对 2020 年 6 月至 2023 年 5 月期间收到的所有乳腺 FNA 进行分类,分别采用 MMSI 和 IAC 横滨系统。以组织病理学诊断为金标准,计算 ROM 和性能参数。
在 559 例乳腺细针抽吸物中,有 337 例可获得组织病理学相关性。非 PBD、无非典型增生的 PBD、有非典型增生的 PBD 和原位癌/癌的 ROM 分别为 0%、1.2%、9.1%和 93%。横滨系统各分类的 ROM 分别为 16.6%、1.1%、4.3%、86.2%和 97.6%。IAC 横滨(97.3%、97.2%、94.7%、98.6%和 97.2%)的敏感性、特异性、PPV、NPV 和诊断准确性稍高于 MMSI(96.4%、96.2%、93%、98.1%和 96.3%)。此外,MMSI 的另一个缺点是无法比较横滨系统的“不充分”类别。
总的来说,横滨系统在对 FNAB 上的乳腺病变进行分类方面被证明是一种更好的系统,因为评分系统提供了更客观的分类,并最大限度地减少了假阳性和假阴性病例。